Baseline clinical characteristics of patients with nm-PMBLsig+ tumors, other DLBCLs, or bf-PMBL
| Characteristic . | Other DLBCLs (n = 306) . | nm-PMBLsig+ (n = 16) . | bf-PMBL (n = 73) . | ||
|---|---|---|---|---|---|
| n (% of total) . | P* . | n (% of total) . | P† . | n (% of total) . | |
| Age, y | .42 | <.001 | |||
| Median | 64 | 66 | 33 | ||
| Range | 16-92 | 19-80 | 13-58 | ||
| Sex | .26 | .41 | |||
| Male | 196 (64) | 8 (50) | 29 (40) | ||
| Female | 110 (36) | 8 (50) | 44 (60) | ||
| ECOG PS | .54 | .45 | |||
| ≤1 | 205 (68) | 12 (75) | 47 (65) | ||
| >1 | 98 (32) | 4 (25) | 25 (35) | ||
| Unknown | 3 | — | 1 | ||
| Serum LDH level | .51 | .006 | |||
| Normal | 134 (48) | 9 (56) | 16 (22) | ||
| Elevated | 146 (52) | 7 (44) | 57 (78) | ||
| Unknown | 26 | — | — | ||
| Ann Arbor stage | .50 | .13 | |||
| I/II | 144 (48) | 9 (56) | 54 (75) | ||
| III/IV | 159 (52) | 7 (44) | 18 (25) | ||
| Unknown | 3 | — | 1 | ||
| B symptoms | .12 | <.001 | |||
| Absent | 187 (62) | 13 (81) | 14 (19) | ||
| Present | 115 (38) | 3 (19) | 58 (81) | ||
| Unknown | 4 | — | 1 | ||
| IPI | .78 | .50 | |||
| 0-2 | 192 (65) | 11 (69) | 51 (75) | ||
| >2 | 102 (35) | 5 (31) | 17 (25) | ||
| Unknown | 12 | — | 5 | ||
| Bulky disease (≥10 cm) | .08 | <.001 | |||
| No | 219 (74) | 15 (94) | 39 (46) | ||
| Yes | 77 (26) | 1 (6) | 28 (54) | ||
| Unknown | 10 | — | 1 | ||
| COO (Lymph2Cx) | .012 | .40 | |||
| GCB | 170 (56) | 14 (88) | 57 (78) | ||
| Non-GCB | 136 (44) | 2 (13) | 16 (22) | ||
| No. of identified extranodal sites | .38 | .007 | |||
| 0 or 1 | 261 (86) | 15 (94) | 28 (51) | ||
| ≥2 | 42 (14) | 1 (6) | 27 (49) | ||
| Unknown | 3 | — | 18 | ||
| Involvement of extranodal sites of interest | |||||
| Bone marrow | .43 | <.001 | |||
| Not identified | 269 (88) | 13 (81) | 73 (100) | ||
| Identified | 37 (12) | 3 (19) | 0 (0) | ||
| Pericardial effusion | .82 | .004 | |||
| Not identified | 305 (100) | 16 (100) | 47 (64) | ||
| Identified | 1 (0) | 0 (0) | 26 (36) | ||
| Pleural effusion | .52 | .045 | |||
| Not identified | 296 (97) | 15 (94) | 51 (70) | ||
| Identified | 10 (3) | 1 (6) | 22 (30) | ||
| Lung | .08 | .33 | |||
| Not identified | 295 (96) | 14 (88) | 56 (77) | ||
| Identified | 11 (4) | 2 (12) | 17 (23) | ||
| Characteristic . | Other DLBCLs (n = 306) . | nm-PMBLsig+ (n = 16) . | bf-PMBL (n = 73) . | ||
|---|---|---|---|---|---|
| n (% of total) . | P* . | n (% of total) . | P† . | n (% of total) . | |
| Age, y | .42 | <.001 | |||
| Median | 64 | 66 | 33 | ||
| Range | 16-92 | 19-80 | 13-58 | ||
| Sex | .26 | .41 | |||
| Male | 196 (64) | 8 (50) | 29 (40) | ||
| Female | 110 (36) | 8 (50) | 44 (60) | ||
| ECOG PS | .54 | .45 | |||
| ≤1 | 205 (68) | 12 (75) | 47 (65) | ||
| >1 | 98 (32) | 4 (25) | 25 (35) | ||
| Unknown | 3 | — | 1 | ||
| Serum LDH level | .51 | .006 | |||
| Normal | 134 (48) | 9 (56) | 16 (22) | ||
| Elevated | 146 (52) | 7 (44) | 57 (78) | ||
| Unknown | 26 | — | — | ||
| Ann Arbor stage | .50 | .13 | |||
| I/II | 144 (48) | 9 (56) | 54 (75) | ||
| III/IV | 159 (52) | 7 (44) | 18 (25) | ||
| Unknown | 3 | — | 1 | ||
| B symptoms | .12 | <.001 | |||
| Absent | 187 (62) | 13 (81) | 14 (19) | ||
| Present | 115 (38) | 3 (19) | 58 (81) | ||
| Unknown | 4 | — | 1 | ||
| IPI | .78 | .50 | |||
| 0-2 | 192 (65) | 11 (69) | 51 (75) | ||
| >2 | 102 (35) | 5 (31) | 17 (25) | ||
| Unknown | 12 | — | 5 | ||
| Bulky disease (≥10 cm) | .08 | <.001 | |||
| No | 219 (74) | 15 (94) | 39 (46) | ||
| Yes | 77 (26) | 1 (6) | 28 (54) | ||
| Unknown | 10 | — | 1 | ||
| COO (Lymph2Cx) | .012 | .40 | |||
| GCB | 170 (56) | 14 (88) | 57 (78) | ||
| Non-GCB | 136 (44) | 2 (13) | 16 (22) | ||
| No. of identified extranodal sites | .38 | .007 | |||
| 0 or 1 | 261 (86) | 15 (94) | 28 (51) | ||
| ≥2 | 42 (14) | 1 (6) | 27 (49) | ||
| Unknown | 3 | — | 18 | ||
| Involvement of extranodal sites of interest | |||||
| Bone marrow | .43 | <.001 | |||
| Not identified | 269 (88) | 13 (81) | 73 (100) | ||
| Identified | 37 (12) | 3 (19) | 0 (0) | ||
| Pericardial effusion | .82 | .004 | |||
| Not identified | 305 (100) | 16 (100) | 47 (64) | ||
| Identified | 1 (0) | 0 (0) | 26 (36) | ||
| Pleural effusion | .52 | .045 | |||
| Not identified | 296 (97) | 15 (94) | 51 (70) | ||
| Identified | 10 (3) | 1 (6) | 22 (30) | ||
| Lung | .08 | .33 | |||
| Not identified | 295 (96) | 14 (88) | 56 (77) | ||
| Identified | 11 (4) | 2 (12) | 17 (23) | ||
Bold P values indicate significance.
ECOG PS, Eastern Cooperative Oncology Group performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase.
Compared with other DLBCLs using the Wilcoxon rank sum test for continuous data (age) and χ2 (Pearson χ2 test) for categorical data.
Compared with bf-PMBL using the Wilcoxon rank sum test for continuous data (age) and χ2 (Pearson χ2 test) for categorical data.